Editor: Jennelle Kyd
CpG oligodeoxynucleotides protect mice from lethal challenge with Candida albicans via a pathway involving tumor necrosis factor-α-dependent interleukin-12 induction
Article first published online: 11 JUL 2007
FEMS Immunology & Medical Microbiology
Volume 51, Issue 1, pages 155–162, October 2007
How to Cite
Choi, J.-H., Ko, H.-M., Park, S. J., Kim, K.-J., Kim, S.-H. and Im, S.-Y. (2007), CpG oligodeoxynucleotides protect mice from lethal challenge with Candida albicans via a pathway involving tumor necrosis factor-α-dependent interleukin-12 induction. FEMS Immunology & Medical Microbiology, 51: 155–162. doi: 10.1111/j.1574-695X.2007.00292.x
- Issue published online: 20 JUL 2007
- Article first published online: 11 JUL 2007
- Received 12 January 2007; revised 23 May 2007; accepted 28 May 2007.First published online 11 July 2007.
- Candida albicans;
In this study, we have attempted to determine whether the systemic administration of CpG oligodeoxynucleotide (CpG-ODN) 1826 would protect mice against systemic lethal Candida albicans infection. CpG-ODNs were found completely to protect mice from death and also reduced the growth of C. albicans in the kidneys. The administration of CpG-ODNs resulted in early interleukin (IL)-12 mRNA expression in the kidneys and an increase in serum IL-12 levels. The protective activity of CpG-ODN was abolished in IL-12-deficient (IL-12−/−) mice, thereby indicating the IL-12-dependency inherent to the effects of CpG-ODN. The protective effect of CpG-ODN was not associated with the activity of NF-κB. Interestingly, in tumor necrosis factor (TNF)-α-deficient (TNF−/−) mice CpG-ODN neither exerted protective effects nor induced IL-12 expression. These data indicate that CpG-ODN protects animals against lethal C. albicans challenge via a pathway that involves the TNF-α-dependent induction of IL-12.